ADHD Medication in the US: Adderall, Vyvanse, Strattera & More (2026)
ADHD medication options in the United States are extensive, with dozens of brand names and generics available. Whether you're considering your first prescription or adjusting your current regimen, understanding the differences between stimulants, non-stimulants, costs, and DEA scheduling is essential for making informed decisions with your prescriber.
Disclaimer: This is educational information, not medical advice. Always consult your prescribing clinician before making any medication decisions.
US-Approved ADHD Medications: Complete Overview
| Medication | Brand Name | Type | Typical Dose Range | Duration |
|---|---|---|---|---|
| Amphetamine salts | Adderall XR, Adzenys XR-ODT | Stimulant | 5–40 mg/day | 8–12 hours |
| Lisdexamfetamine | Vyvanse | Stimulant | 20–70 mg/day | 10–13 hours |
| Methylphenidate | Ritalin XR, Concerta, Cotempla XR-ODT | Stimulant | 10–72 mg/day | 8–12 hours |
| Atomoxetine | Strattera | Non-stimulant | 40–100 mg/day | 24 hours |
| Viloxazine ER | Qelbree | Non-stimulant | 100–600 mg/day | 24 hours |
| Guanfacine ER | Intuniv | Non-stimulant | 1–4 mg/day | 24 hours |
Stimulant Medications: Amphetamines & Methylphenidate
Amphetamine Salts (Adderall, Adderall XR)
Amphetamine salts combine 75% amphetamine aspartate and 25% amphetamine base, creating a balanced stimulant effect. Adderall XR is extended-release and typically prescribed once daily.
- Onset: 30–60 minutes for immediate-release; 1–2 hours for XR
- Duration: 4–6 hours (IR); 8–12 hours (XR)
- Typical adult dose: 10–40 mg/day
- Cost: Generic amphetamine salts ~$10–40/month; brand Adderall XR ~$150–300/month without insurance
- Strength: Potent stimulant; often considered most effective for moderate–severe ADHD
Methylphenidate (Ritalin, Concerta, Ritalin LA)
Methylphenidate is chemically distinct from amphetamine but produces similar ADHD symptom improvements. Extended-release formulations reduce dosing frequency.
- Immediate-release (Ritalin): Takes effect in 30 minutes, lasts 3–5 hours. Good for flexible dosing.
- Extended-release (Ritalin XR, Concerta): Lasts 8–12 hours. Concerta uses osmotic pump technology for steady release.
- Typical adult dose: 20–72 mg/day
- Cost: Generic methylphenidate ~$15–50/month; brand Concerta ~$200–350/month without insurance
Lisdexamfetamine (Vyvanse)
Vyvanse is a prodrug requiring hepatic metabolism to become active. This design reduces abuse potential compared to immediate-release amphetamine formulations.
- Onset: 60–90 minutes (slower, smoother onset)
- Duration: 10–13 hours
- Typical adult dose: 30–70 mg/day
- Cost: Brand only; typically $150–300/month without insurance (generic unavailable until 2026)
- Advantage: Single daily dose; lower abuse potential; smoother concentration curve
Non-Stimulant Medications
Atomoxetine (Strattera)
A noradrenaline reuptake inhibitor (NRI) with no abuse potential. Useful if stimulants cause anxiety, insomnia, or cardiovascular concerns.
- Onset: 2–4 weeks for maximum benefit
- Duration: 24 hours
- Typical adult dose: 60–100 mg/day
- Cost: Generic ~$30–80/month; brand Strattera ~$200–250/month
- Drawback: Slower onset means weeks before full effect; some report less improvement than stimulants
Viloxazine ER (Qelbree)
Approved by FDA in 2021, viloxazine is a selective noradrenaline reuptake inhibitor with longer half-life than atomoxetine. Newer option for patients seeking non-stimulant alternatives.
- Onset: 1–2 weeks
- Duration: 24 hours
- Typical adult dose: 200–600 mg/day
- Cost: Brand only; typically $250–350/month without insurance
- Advantage: Faster onset than atomoxetine; no abuse potential
Guanfacine ER (Intuniv)
An alpha-2A agonist effective for impulse control and hyperactivity-driven symptoms. Often used in combination with stimulants or as monotherapy.
- Onset: 1–3 weeks
- Duration: 24 hours
- Typical adult dose: 1–4 mg/day
- Cost: Generic ~$25–60/month; brand Intuniv ~$150–250/month
DEA Scheduling & Controlled Drug Restrictions
Understanding DEA scheduling is crucial for insurance, refill policies, and prescriber authorization:
| Schedule | Medications | Refill Rules |
|---|---|---|
| Schedule II (highest control) | Amphetamine salts, methylphenidate, lisdexamfetamine, other amphetamines | No refills; new prescription every 30 days. Electronic prescriptions preferred. No automatic refills. |
| Schedule III | Phendimetrazine | Max 5 refills within 6 months |
| Non-controlled | Atomoxetine, viloxazine, guanfacine | Standard refill rules; automatic refills permitted |
Generic vs. Brand: Cost & Effectiveness
Generic drugs are FDA-approved bioequivalent to brand-name medications, meaning they have the same active ingredient and efficacy. However, differences in fillers and manufacturing can occasionally cause tolerability variations.
- Generic stimulants: ~$10–50/month; usually first-line choice due to cost
- Brand stimulants: ~$150–350/month without insurance; some patients report better tolerance due to consistent manufacturing
- Vyvanse: Brand only until 2026. Patent expiration expected late 2026 will drive generic costs down significantly
- Insurance tip: Request generic first; switch to brand only if generic fails or causes side effects. Document why in medical records.
Current ADHD Medication Shortages (2026 Update)
Amphetamine shortages have been ongoing since 2022 due to DEA manufacturing quotas. As of April 2026:
- Adderall XR: Intermittent shortages; generics more reliably available than brand
- Methylphenidate (all formulations): Stable supply; generally no shortages
- Vyvanse: Stable supply; no shortages reported
- Non-stimulants: Stable; alternative if stimulant shortages affect you
Shortage tip: Ask your prescriber about methylphenidate as alternative if amphetamine salts unavailable. Similar efficacy for most patients.
Insurance Coverage & Prior Authorization
Most insurance plans cover ADHD medications, but formulary restrictions and prior authorization requirements vary:
- Generic stimulants: Usually covered with minimal or no prior authorization
- Brand-name medications: Often require prior authorization (PA) and may require failure of generic first
- Prior auth process: Prescriber submits clinical justification; insurance responds in 24–72 hours
- Appeals: If denied, you can appeal with additional clinical evidence from your provider
Testing Before Starting Medication
Comprehensive baseline assessments help you understand your ADHD profile and provide data to share with your prescriber:
- Focus & Energy Check-In — Assess inattention, hyperactivity, and impulsivity severity
- Neurodivergence Profile — Get a full neurodivergent profile including ADHD and autism traits
Key Takeaways
- Three main stimulant classes: amphetamine salts (Adderall), methylphenidate (Ritalin/Concerta), and lisdexamfetamine (Vyvanse)
- Non-stimulants (atomoxetine, viloxazine, guanfacine) are safer alternatives if stimulants cause side effects or contraindications
- Schedule II stimulants require new prescription every 30 days; no automatic refills
- Generic medications are bioequivalent and cost 80–90% less than brand; start here
- Amphetamine shortages remain intermittent; methylphenidate is more reliable alternative
- Insurance coverage varies; prior authorization often required for brand medications
References
- American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental Disorders (5th ed.). Arlington, VA: American Psychiatric Publishing.
- Wolraich, M. L., Hagan, J. F., Allan, C., Chan, E., Davignon, L., Earls, M. F., & Zurhellen, W. (2019). Clinical practice guideline for the evaluation and treatment of children and adolescents with ADHD. Pediatrics, 144(4), e20192528.
- Cortese, S., Asherson, P., Sonuga-Barke, E., & Banaschewski, T. (2020). ADHD management in adults: a European consensus statement. European Psychiatry, 59, 56–69.
- United States Food and Drug Administration (FDA). Approved medications for ADHD. 2026. www.fda.gov
- Drug Enforcement Administration (DEA). Orange Book: Approved Drug Products. 2026. www.dea.gov